Scholarlink

<p>Neoangiogenesis is a fundamental driver of tumor progression, intricately governed by various signaling pathways. In the tumor microenvironment (TME), extravasated red blood cells (RBCs) and endothelial-lined blood vessels are now recognized as potential modulators of tumor cell dynamics, with critical roles in recurrence patterns. Our study presents two cases suggesting that these vascular-like formations may either originate autonomously within the tumor epithelium or reflect a tumor-driven atypical stromal response. We put forth the hypothesis that cross-talk among tumor cells, endothelial-lined vessels, and heme carriers e.g., SLC48A1 or HRG1 in RBCs could influence tumor progression and overall patient prognosis. Recognizing these hemangiomatous formations as unique pathological entities could pave the way for targeted therapies that directly address these structures, enhancing treatment precision. Such tailored interventions could disrupt the pro-tumorigenic influence of these vascular elements, potentially leading to improved prognostic outcomes and greater therapeutic benefits for patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of HRG1 in Neoangiogenesis and Tumor Microenvironment Complexity: A New Perspective

  • 期刊论文

  • 发表日期：

    2026年2月9日

查看全文
  • Sharon John,
  • Arushi Tomar,
  • Ayushi Jain,
  • Shalini Gupta

摘要

Neoangiogenesis is a fundamental driver of tumor progression, intricately governed by various signaling pathways. In the tumor microenvironment (TME), extravasated red blood cells (RBCs) and endothelial-lined blood vessels are now recognized as potential modulators of tumor cell dynamics, with critical roles in recurrence patterns. Our study presents two cases suggesting that these vascular-like formations may either originate autonomously within the tumor epithelium or reflect a tumor-driven atypical stromal response. We put forth the hypothesis that cross-talk among tumor cells, endothelial-lined vessels, and heme carriers e.g., SLC48A1 or HRG1 in RBCs could influence tumor progression and overall patient prognosis. Recognizing these hemangiomatous formations as unique pathological entities could pave the way for targeted therapies that directly address these structures, enhancing treatment precision. Such tailored interventions could disrupt the pro-tumorigenic influence of these vascular elements, potentially leading to improved prognostic outcomes and greater therapeutic benefits for patients.